1. Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis
- Author
-
Ting Li, Lingfang Niu, Luo Li, Chunli Luo, Yan Zhao, Chaowen Yu, Xiaohou Wu, Limei Duan, Zhenting He, and Lin Zou
- Subjects
Male ,medicine.medical_specialty ,Nitrogen ,Urology ,Prostatic Hyperplasia ,Urine ,urologic and male genital diseases ,Gastroenterology ,Gas Chromatography-Mass Spectrometry ,Prostate cancer ,chemistry.chemical_compound ,Metabolomics ,Internal medicine ,medicine ,Humans ,Metabolic Marker ,Aged ,Fatty acid metabolism ,business.industry ,Prostate ,Prostatic Neoplasms ,Reproducibility of Results ,Organ Size ,Prostate-Specific Antigen ,Hyperplasia ,medicine.disease ,Metabolic pathway ,Oncology ,chemistry ,Urea cycle ,Energy Metabolism ,business ,Metabolic Networks and Pathways ,Chromatography, Liquid - Abstract
OBJECTIVE Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men which is associated with profound metabolic changes. Systematic analysis of the metabolic alterations and identification of new biomarkers may benefit PCa diagnosis and a deep understanding of the pathological mechanism. The purpose of this study was to determine the metabolic features of PCa. METHODS Plasma and urine metabolites from 89 prostate cancer (PCa) patients, 84 benign prostatic hyperplasia (BPH) patients, and 70 healthy males were analyzed using LC-MS/MS and GC-MS. The Orthogonalised Partial Least Squares Discriminant Analysis (OPLS-DA) was used to find the significantly changed metabolites. The clinical value of the candidate markers was examined by receiver operating characteristic curve analysis and compared with prostate-specific antigen (PSA). RESULTS Multivariate statistical analyses found a series of altered metabolites, which related to the urea cycle, tricarboxylic acid cycle (TCA), fatty acid metabolism, and the glycine cleavage system. Plasma Glu/Gln showed the highest predictive value (AUC = 0.984) when differentiating PCa patients from healthy controls, with a higher sensitivity than PSA (96.6% vs. 94.4%). Both Glu/Gln and PSA displayed a low specificity when differentiating PCa patients from BPH patients (
- Published
- 2021